74 related articles for article (PubMed ID: 22017464)
21. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study.
Kim YH; Chung HH; Kang SB; Kim SC; Kim YT
Acta Haematol; 2009; 121(1):37-41. PubMed ID: 19332985
[TBL] [Abstract][Full Text] [Related]
22. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.
Zheng H; Huang X; Zhang Q; Katz SD
Kidney Int; 2006 Feb; 69(4):679-84. PubMed ID: 16395269
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
24. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
25. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
26. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
27. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
28. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
29. Intravenous iron sucrose changes the intraperitoneal homeostasis.
Breborowicz A; Połubinska A; Kupczyk M; Wanic-Kossowka M; Oreopoulos DG
Blood Purif; 2009; 28(1):53-8. PubMed ID: 19325240
[TBL] [Abstract][Full Text] [Related]
30. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
31. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
32. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
34. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
35. Endothelial dysfunction and oxidative stress in chronic renal failure.
Ghiadoni L; Cupisti A; Huang Y; Mattei P; Cardinal H; Favilla S; Rindi P; Barsotti G; Taddei S; Salvetti A
J Nephrol; 2004; 17(4):512-9. PubMed ID: 15372412
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
38. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
Westad S; Backe B; Salvesen KA; Nakling J; Økland I; Borthen I; Rognerud Jensen OH; Kolås T; Løkvik B; Smedvig E
Acta Obstet Gynecol Scand; 2008; 87(9):916-23. PubMed ID: 18720044
[TBL] [Abstract][Full Text] [Related]
39. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
[TBL] [Abstract][Full Text] [Related]
40. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]